Innoviva, Inc. Share Price & Technical Analysis
INVA · $22.44 (+1.08%)
Healthcare / Biotechnology
$22.44
+1.08%
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The comp…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
-2% return in May, 8% avg return in past 3 year May month.
13% return in 2026, 16% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 1% | 15% | 2% | -2% | -2% | – | – | – | – | – | – | – | 13% |
| 25 | 6% | -4% | 2% | 4% | 5% | 3% | -9% | 10% | -11% | 0% | 20% | -7% | 17% |
| 24 | 2% | -6% | -9% | -1% | 4% | 3% | 15% | 8% | -1% | 2% | -4% | -8% | 5% |
| 23 | -5% | -4% | -7% | 4% | 15% | -6% | 8% | -5% | 2% | -5% | 13% | 14% | 24% |
| 22 | -7% | 19% | 1% | -12% | -10% | -3% | -3% | -8% | -11% | 16% | -4% | 0% | -20% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Neutral
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.68B
P/E ratio
3.63
52W high
$25.15
52W low
$16.52
Volume
9,68,272
Beta
0.38
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Innoviva, Inc. share price today?
- Innoviva, Inc. (INVA) last traded around $22.44 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does INVA have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for INVA. Download the app for real-time alerts.
- How can I analyze Innoviva, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.